- Home
- CHRW vs NBIX Comparison
CHRW vs NBIX Comparison
Compare CHRW & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRW
- NBIX
- Stock Information
- Founded
- CHRW 1905
- NBIX 1992
- Country
- CHRW United States
- NBIX United States
- Employees
- CHRW N/A
- NBIX N/A
- Industry
- CHRW Oil Refining/Marketing
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CHRW Consumer Discretionary
- NBIX Health Care
- Exchange
- CHRW Nasdaq
- NBIX Nasdaq
- Market Cap
- CHRW 12.9B
- NBIX 13.1B
- IPO Year
- CHRW 1997
- NBIX 1996
- Fundamental
- Price
- CHRW $107.89
- NBIX $135.45
- Analyst Decision
- CHRW Buy
- NBIX Buy
- Analyst Count
- CHRW 17
- NBIX 23
- Target Price
- CHRW $113.07
- NBIX $165.00
- AVG Volume (30 Days)
- CHRW 1.2M
- NBIX 910.2K
- Earning Date
- CHRW 01-29-2025
- NBIX 02-05-2025
- Dividend Yield
- CHRW 2.27%
- NBIX N/A
- EPS Growth
- CHRW N/A
- NBIX 97.40
- EPS
- CHRW 2.89
- NBIX 3.73
- Revenue
- CHRW $17,762,187,000.00
- NBIX $2,242,800,000.00
- Revenue This Year
- CHRW $4.28
- NBIX $27.07
- Revenue Next Year
- CHRW $2.13
- NBIX $16.60
- P/E Ratio
- CHRW $37.28
- NBIX $36.12
- Revenue Growth
- CHRW N/A
- NBIX 25.72
- 52 Week Low
- CHRW $65.00
- NBIX $110.95
- 52 Week High
- CHRW $114.82
- NBIX $157.98
- Technical
- Relative Strength Index (RSI)
- CHRW 50.83
- NBIX 68.12
- Support Level
- CHRW $106.54
- NBIX $125.61
- Resistance Level
- CHRW $114.82
- NBIX $130.48
- Average True Range (ATR)
- CHRW 2.83
- NBIX 2.92
- MACD
- CHRW 0.18
- NBIX 0.72
- Stochastic Oscillator
- CHRW 40.84
- NBIX 69.33
About CHRW C.H. Robinson Worldwide Inc.
C.H. Robinson is a top-tier non-asset-based third-party logistics provider with a significant focus on domestic freight brokerage (about 61% of net revenue), which reflects mostly truck brokerage but also rail intermodal. Additionally, the firm operates a large air and ocean forwarding division (27%), which has grown organically and via tuck-in acquisitions over the years. The remainder of revenue consists of the European truck-brokerage division, transportation management services, and a legacy produce-sourcing operation.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.